Clinical Trial Results:
Extensión de 38 semanas del Estudio Fase III, multicéntrico, aleatorizado con doble enmascaramiento, controlado con placebo, de determinación de dosis y 24 semanas de duración, con el objetivo de evaluar el AIN457 frente a placebo en el mantenimiento de la supresión de la actividad de la uveitis quiescente no infecciosa intermedia, posterior o panuveitis tras la reducción del tratamiento inmunosupresor sistémico (Estudio ENDURE)
Summary
|
|
EudraCT number |
2009-015508-24 |
Trial protocol |
ES GB DE IT |
Global completion date |
15 Jul 2011
|
Paediatric regulatory details
|
|
Is the trial part of an agreed EMA paediatric investigation plan? |
No
|
Is the trial in scope of article 45 of Regulation (EC) No 1901/2006? |
No
|
Is the trial in scope of article 46 of Regulation (EC) No 1901/2006? |
No
|
Results information
|
|
Results version number |
v1(current) |
This version publication date |
21 Apr 2016
|
First version publication date |
21 Apr 2016
|
Other versions |
|
Summary report(s) |
CAIN457C2301E1_CT_gov_results |
Note: The legislation allows summary attachments to be posted instead of the full dataset for this trial. Refer to Commission Guideline 2012/C 302/03
for further information.